The Column Group to Acquire NGM Biopharmaceuticals

Paul, Weiss is advising entities of The Column Group, LP in their take-private acquisition of NGM Biopharmaceuticals, Inc., a biotechnology company focused on transformative therapeutics. Under the terms of the deal, Atlas Neon Parent, Inc. and its affiliate Atlas Neon Merger Sub, Inc., both entities affiliated with The Column Group, will acquire NGM Bio through a cash tender offer for all outstanding shares of the company at a price per share of $1.55. The Column Group, along with other existing stockholders, will contribute their shares to the purchasing entity as part of the transaction rather than receive the cash offer.

The Column Group is NGM Bio’s longest and largest stockholder, holding approximately 26% of its outstanding shares. The acquisition is expected to close in the second quarter of 2024, subject to customary closing conditions.

The Paul, Weiss team is led by corporate partners Austin Pollet and Luke Jennings, and includes, among others, executive compensation partner Andrea Wahlquist Brown and counsel Sasha Belinkie and Christopher Gonnella; intellectual property partner Jonathan Ashtor; tax partner Matthew Jordan; and litigation counsel Steven Herzog.